What happens to stocks if AI loses momentum?
On Monday, Citi analyst Yigal Nochomovitz adjusted Arvinas Inc.’s (NASDAQ:ARVN) price target, reducing it to $9.50 from the previous $10.00, while retaining a Neutral stance on the stock. According to InvestingPro data, the stock has experienced significant volatility, with shares down over 71% in the past six months, though current analysis suggests the stock may be undervalued at its present level of $7.72. The revision follows Pfizer (NYSE:PFE)’s decision to halt further development of certain Phase 3 combination trials involving vepdeg, a drug for which Arvinas and Pfizer have been collaborating.
The discontinued trials include combinations with vepdeg in first-line treatments (1L +atirmo) and second-line treatments (+CDK4/6). Pfizer’s move reflects the challenges posed by missed endpoints in the VERITAC-2 study and the emergence of competitive data from other selective estrogen receptor degrader (SERD) therapies, such as Roche’s giredestrant and AstraZeneca (NASDAQ:AZN)’s camizestrant. Despite these setbacks, InvestingPro data shows Arvinas maintains a strong financial position with a current ratio of 4.58 and more cash than debt on its balance sheet.
Nochomovitz noted that the complexity of conducting novel Phase 3 combination trials, which could have required intricate trial designs, might have influenced Pfizer’s decision, although it likely was not the primary reason. With Pfizer stepping back from these particular trials, Arvinas is expected to focus its efforts on launching vepdeg for a more specific patient population: those with second-line plus ESR1 mutations (2L+ ESR1m). This decision is based on the positive data yielded from the VERITAC-2 trial for this subgroup.
However, the analyst pointed out that even within this narrower market, Arvinas faces significant competition. Orserdu has established a market lead, and Eli Lilly (NYSE:LLY)’s imlunestrant is anticipated to enter the market for ESR1 mutations following the EMBER-3 study, which is expected to conclude in the fourth quarter of 2024.
The report reflects the dynamic nature of the pharmaceutical industry, where drug development strategies are frequently adjusted in response to clinical trial outcomes and the competitive landscape. Arvinas and Pfizer’s strategic pivot underscores the importance of focusing on areas where clinical data shows the most promise while navigating the challenges of an evolving market. For deeper insights into Arvinas’s financial health and market position, InvestingPro subscribers can access comprehensive analysis, including 13 additional ProTips and detailed valuation metrics in the Pro Research Report.
In other recent news, Arvinas Inc. has faced multiple downgrades and price target reductions from several analyst firms following significant developments in its drug pipeline. Truist Securities downgraded Arvinas from a Buy to a Hold, slashing the price target to $11, citing a narrower total addressable market for its lead product candidate, Vepdeg, in breast cancer treatments. Similarly, BTIG reduced its price target to $16 from $69, maintaining a Buy rating, after Arvinas and Pfizer decided to discontinue Phase 3 trials for combination therapies, influenced by limited applications for Selective Estrogen Receptor Degraders. TD Cowen also downgraded the stock to Hold due to the canceled trials, which were initially seen as a significant market opportunity.
Jefferies followed suit, cutting its rating to Hold and lowering the price target to $10 from $52, as the anticipated combination therapy was expected to be a major revenue driver. Goldman Sachs adjusted its price target to $8, maintaining a Neutral stance, after Arvinas announced plans to halt Phase 3 trials to focus on cost reduction and extend its cash runway. These strategic changes have led to a reassessment of Arvinas’s market potential, with analysts expressing caution over its future growth prospects. Despite the setbacks, Arvinas aims to concentrate on its early-stage pipeline, hoping to leverage its financial resources for future development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.